Drug Interactions between lindane topical and Uni Tussin PE
This report displays the potential drug interactions for the following 2 drugs:
- lindane topical
- Uni Tussin PE (guaifenesin/pseudoephedrine)
Interactions between your drugs
pseudoephedrine lindane topical
Applies to: Uni Tussin PE (guaifenesin / pseudoephedrine) and lindane topical
MONITOR: Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.
MANAGEMENT: Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.
References (9)
- Telch J, Jarvis DA (1982) "Acute intoxication with lindane (gamma benzene hexachloride)." Can Med Assoc J, 126, p. 662-3
- Munk ZM, Nantel A (1977) "Acute lindane poisoning with development of muscle necrosis." Can Med Assoc J, 117, p. 1050-4
- Tenenbein M (1991) "Seizures after lindane therapy." J Am Geriatr Soc, 39, p. 394-5
- Pramanik AK, Hansen RC (1979) "Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children." Arch Dermatol, 115, p. 1224-5
- Matsuoka LY (1981) "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol, 5, p. 98-9
- Solomon BA, Haut SR, Carr EM, Shalita AR (1995) "Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem." J Fam Pract, 40, p. 291-6
- "Product Information. Kwell (lindane)." Reed and Carnrick, Jersey City, NJ.
- Ramchander V, Cameron ES, Reid HF (1991) "Lindane toxicity in an infant." West Indian Med J, 40, p. 41-3
- Cox R, Krupnick J, Bush N, Houpt A (2000) "Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder." J Miss State Med Assoc, 41, p. 690-2
Drug and food interactions
pseudoephedrine food
Applies to: Uni Tussin PE (guaifenesin / pseudoephedrine)
MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.
MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.
References (7)
- Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
- Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
- (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
- (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
- (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
- (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
- (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.